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ABSTRACT
It has been found that antimuscarinic drugs, viewed as the “gold standard” in overactive bladder syndrome (OAB) treatment, 
have an unsatisfactory tolerance profile and limited clinical effectiveness. This fact has given a clear impetus to search for 
new options in OAB pharmacotherapy. The conducted pre-clinical trials have led to the development of new solutions for 
the treatment of OAB, which stand a good chance of being applied in clinical practice. The said compounds are characterised 
by higher receptor and organ specificity than currently used medications. 
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INTRODUCTION
The review of the current state of knowledge on the 
perspectives for the pharmacological treatment of OAB is 
presented below. It focuses on the mechanisms of action of 
new compounds at the same time indicating the possibili-
ties for their application in specific groups of patients. Due 
to its complex etiopathogenesis, OAB is seen as “a disease of 
symptoms,” and it seems justified to expect that the future 
pharmacotherapy of this syndrome should be tailored to 
the individual needs of a given patient.
NEW ANTIMUSCARINICS
Due to their proven effectiveness, anticholinergics are 
still the subject of extensive studies which focus on new 
medications with regard to their receptor and organ selec-
tivity, the development of new methods of drug administra-
tion and combined therapies using existing compounds.
Imidafenacin (KRP-197, ONO8025) is a newly-synthe-
sised antimuscarinic agent registered for OAB treatment, 
and launched on the Japanese and Taiwanese markets. It 
shows high selectivity for M3 and M1 receptors, and low 
for M2 receptor, along with organ selectiveness in relation 
to the urinary bladder. The drug inhibits bladder contract-
ibility acting as an M3 receptor antagonist, and modulating 
the release of acetylcholine from the prejunctional facilita-
tory M1 receptors. The meta-analysis of five randomised 
clinical trials devoted to the evaluation of the safety profile 
and efficacy of imidafenacin, which covered 1253 patients, 
did not show any significant differences in the number of 
urge incontinence episodes or the mean number of void-
ings per day, when compared to propiverine or solifenacin. 
Also, differences in OAB index values (OABSS) were not 
found. Imidafenacin proved to have a beneficial effect on 
nocturia and on the polyuria index. Such results, however, 
were not obtained with regard to solifenacin. When com-
pared with propiverine, solifenacin and fesoterodine, they 
produced lower number of constipations and intensification 
of dry-mouth symptoms. The duration of dry-mouth symp-
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toms following the administration of imidafenacin proved 
to be much shorter than with other anticholinergics. It is 
very important that imidafenacin does not affect the cog-
nitive function in elderly patients and does not induce car-
diovascular symptoms typical for anticholinergics, such as 
increased heart rate or the prolongation of the QT interval 
on ECG records. Interestingly, imidafenacin, unlike other 
antimuscarinics, does not increase the plasma concentration 
of digoxin administered at the same time as imidafenacin [1].
Tarafenacin (SVT-40776) is a new quinuclidinol deriva-
tive with high M3 receptor selectivity (an antagonist) and 
low inhibition potential in relation to the submandibular 
gland. It shows a 200 times higher selectivity for M3 recep-
tors than for M2 receptors. The second-phase trials, which 
comprised 235 people receiving tarafenacin in a dose of 
0.2 mg or 0.4 mg, showed a considerable drop in the num-
ber of voidings per day in the group receiving 0.4 mg of the 
drug for 12 weeks, when compared to the placebo group. 
The three groups displayed no differences in the frequency 
of urinary urgency. Dose-response correlation, in turn, was 
found with regard to the increase of dry-mouth and visual 
disorders while the increase in the dose did not exacerbate 
constipations. Tarafenacin is now administered as part of the 
third phase of the clinical trials. The initial results seem to 
indicate that the action of the drug begins quickly, reaching 
maximum blood concentration within 4h after swallowing, 
and T1/2 — within 35 h, as a result of which it can be taken 
once a day. No significant cardiovascular adverse events 
have been noted so far [2].
Afacifenacin (SMP-986) is another anticholinergic agent 
which is now administered in the second phase of the clini-
cal trials. It has a unique mechanism of actions. In addition to 
blocking M receptors, afacifenacin proves to have a blocking 
effect on the sodium channels, leading to the inhibition of 
afferent fibres which supply the urinary bladder. The clini-
cal effect of this drug include a reduction in pollakiuria and 
urge incontinence, and an increase in voiding volume. The 
results of the currently conducted trials indicate that, when 
compared to other antimuscarinics, the drug displays less 
intensified adverse effects, which may stem from the high 
receptor selectivity of this compound.
NEW COMBINATIONS OF DRUGS
Adverse effects, typical of the pharmacotherapy involv-
ing anticholinergics (including especially dry mouth), have 
given a clear impetus for work on a new strategy of complex 
therapy, including the combined application of pilocarpine 
— a quick-acting muscarinic receptor antagonist, character-
ised by high organ selectivity for salivary glands (it stimu-
lates their secretionary function), and an antimuscarinic 
agent. Tolenix (THVD-201) is a combination of tolterodine 
IR (2 mg) and pilocarpine ER (9 mg). 138 people randomly 
assigned to one of the three groups — receiving tolenix, 
tolterodine or the placebo — were subjected to observa-
tions. When compared to the placebo group, the other two 
displayed a reduction in OAB symptoms in the form of void-
ing frequency reduction and a lower number of urge incon-
tinence episodes, but they suffered from strong dry-mouth 
effect. Importantly, significant drops in dry mouth, difficulty 
in swallowing, chewing and falling asleep in the Tolenix 
group were noted, when compared to the patients receiving 
tolterodine IR. Urge incontinence episodes were found to be 
slightly more frequent in the group receiving Tolenix than in 
the patients receiving tolterodine. The Tolenix group had low 
visual analogue scores for dry mouth. Salivary gland secre-
tion did not change after 3 h of the administration of Tolenix, 
but it became significantly lower after the administration of 
tolterodine IR. The medication is currently subjected to the 
third phase of clinical trials [3].
β3 RECEPTOR AGONISTS
Solabegron (GW427353) is a new β3 receptor agonist, 
currently undergoing clinical tests. The previous in vitro tests 
on the urinary bladder sections showed that this medication 
caused an 82% relaxation of the bladder tissue. Also, the 
degree of selectivity of solabegron for β1, β2 and β3 receptors 
was determined. This selectivity was measured by observing 
the cAMP increase. Following the solabegron administra-
tion, the cAMP increased by 90% in the cells containing 
β3 receptors, and by only < 10% in those cells which had 
β1 and β2 receptors. Interestingly, selective antagonists of 
β1 and β2 receptors lacked the relaxant potential of solabe-
gron. In vitro tests also showed that solabegron reinforced 
the relaxant effect induced by oksybutynin, tolterodine, or 
solifenacin, and is a much stronger relaxant agent than mi-
rabegron. At present, the second phase of the clinical trials is 
conducted, aiming at assessing this interaction. In vivo tests 
have proven that the drug increases voiding volume by 22%. 
The second phase of the trials devoted to the examining of 
its effectiveness covered 258 patients who were divided 
into three groups — a placebo group and two groups re-
ceiving 50 and 125 mg of the medicine, respectively, every 
12 h. After 8 weeks of treatment a significant decrease in 
the number of urge incontinence episodes was noted in 
both study groups, with the same degree of dry mouth and 
constipation as in the placebo group. A drop in the voiding 
frequency, and an increase in voiding volume and volume 
threshold to elicit nonvoiding contractions (VTNVC) values, 
in the urodynamic test were noted in the group of patients 
receiving higher doses of the drug. No significant changes 
were found with regards to arterial pressure, or alarming 
symptoms visible on ECG [4].
It is believed that β3 receptor agonists might become 
second-line medications in those OAB patients who poorly 
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respond to treatment with antimuscarinics and do not toler-
ate them, or when there is a risk of urine retention.
NEW STRATEGIES FOR BOTULINUM TOXIN 
ADMINISTRATION
While administering the botulinum toxins clinicians usu-
ally avoid the urinary bladder triangle due to the risk of mus-
cle irritation and vesicoureteral reflux. A comparative study 
of cases in which the toxin was administered within and 
outside the triangle, as well as to both those sites, showed no 
differences in the effectiveness of the treatment or adverse 
effects frequency. In one of the trials conducted in a group 
of 22 people, the injections to the triangle were found to 
be more effective when compared to the injections outside 
the bladder triangle. The patients were given 500 units of 
neurotoxin in 20 mL, in 20 injections. A primary final point 
was the assessment of the OAB index. OABSS improved 
from 22.4 to 8.7 in the group which was injected inside the 
triangle and from 22.7 to 13.4 in the group receiving neu-
rotoxin outside this area. No differences in PVR were noted.
Clinical trials are also conducted with the aim of evaluat-
ing the effectiveness of the intravesical instillation of botu-
linum toxin combined with liposomes, which is thought 
by the researchers to improve the transport of neurotoxin 
through the urothelium to the detrusor. The trials involved 
the administration of lipotoxins containing 80 mg of li-
posomes and 200 units of A botulinum toxin. The initial re-
sults of the experiments showed that the number of urinary 
urgency and pollakiuria episodes were reduced after one or 
three months following the instillation. Changes in PVR or 
increases in urinary infection frequency were not noted. The 
work aimed at determining the depth of lipotoxin penetra-
tion have not been concluded yet, so it is possible that the 
mechanisms of its action are slightly different from those of 
botulinum toxin injections, due to the transport limitations 
from the urothelium to deeper layers of the bladder. This 
neurotoxin has a high molecular weight (150 KDa), and, if 
it is not injected, it might not be able to reach the afferent 
fibres lying below the urothelium [5].
ANTIDEPRESSANTS
The patients with OAB frequently suffer from various 
mental disorders, among which depression is the most com-
mon. It has been proven that duloxetine produces positive 
therapeutic effects, not only in SUI treatment, but it can also 
be seen as a drug of choice in MS patients experiencing both 
depression and OAB symptoms. Its effectiveness has been 
confirmed during the treatment of patients with both OAB 
wet and OAB dry. Tricyclic antidepressants (imipramine or 
amitriptyline) which increase NA levels through the inhibi-
tion of its reuptake are used as a second-line treatment (off 
label) in people with OAB resistant to antimuscarinic therapy.
Preclinical trials have indicated that the beneficial effect 
which duloxetine has on the OAB symptoms stems from the 
inhibition of sensory afferents by the serotonegic system, 
and also from modulation by the serotonin and noradrena-
line micturition centre in the sacra spinal cord. The results 
of clinical trials have proven that this drug decreases the 
number of frequency and urgency episodes, and improves 
the quality of life scores, while leaving the mean voided 
volume unchanged. No adverse effects have been found 
in relation to the heart rate, blood pressure or arrhytmo-
genic tendencies in EEG. Its clinical efficacy has proven to 
exceed the placebo effects in OAB patients due either to 
detrusor overactivity (DO) or sensory urgency, and in MUI 
patients. Thus, due to the proven clinical effectiveness in 
treating depression, it seems that duloxetine can become 
a drug of choice in patients with depression and coexisting 
OAB symptoms [6].
ANTIEPILEPTIC DRUGS
Gabapentin was first synthesised as an antiepileptic 
drug. Its mechanisms of action are based on blocking the 
sodium channels and the modulation of GABAergic neuro-
transmission. It is currently under clinical trials in the terms 
of its effectiveness in OAB pharmacotherapy. The results to 
date indicate that gabapentin has positive effects on OAB 
symptoms in neurogenic bladder patients, and in patients 
resistant to treatment with anticholinergics. Cystometric 
measurements have shown the reduction in the urodynamic 
symptoms of DO. It has also been found that the combined 
application of gabapentin and NSAID or amitryptyline has 
positive effects on DO symptoms in people with the bladder 
pain syndrome. Pregabin and lamotrigine are drugs with 
structures similar to gabapentin, and it has turned out that 
their administration to patients with neurogenic DO could 
give positive results [7].
TACHYKININ RECEPTORS
The results of the preclinical trials have proven that the 
contractions in the human detrusor muscle induced by 
tachykinins are mediated by the NK2 receptors. The stimula-
tion of these receptors by tachykinins released from afferent 
endings leads to the lowering of the voiding threshold, and, 
as a consequence, to the detrusor overactivity and the oc-
currence of phase contractions. It might suggest that tachy-
kinins participate in supraspinal micturition control, which 
makes NK receptors located in the spinal cord a potential 
target of OAB pharmacotherapy. The results of the clinical 
trials have proven that the antagonists of NK2 receptors in-
hibit hyperreflexia in bacterial cystitis and in cases of spinal 
cord injuries. This opens up a potential for drug application 
in patients with MS and spinal cord injuries accompanied 
by OAB symptoms. One of the antagonists to NK1 receptors 
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which can penetrate the blood-brain barrier is aprepitant, 
which is now used to treat nausea in patients undergoing 
chemotherapy. Randomised clinical trials have shown that 
this drug has a positive effect on urinary frequency and 
urgency episodes. Another antagonist to NK1 receptors 
— serlopitant — has also been tested with regard to its 
effectiveness. It has proven to reduce the number of ur-
gency episodes, whereas its clinical efficacy appears lower 
than that of tolterodine ER [8].
TRPV1 RECEPTORS
Urinary bladder and urethra are characterised by a high 
density of TRPV1 receptors which take part in pain perception 
and bladder contractile activity. A particularly high expression 
of these receptors is found in the urothelium and demyelin-
ised bladder C fibres. TRPV4 receptors, in turn, act as mecha-
noreceptors and play an important role in the regulation of 
bladder excitability and contractibility. Preclinical trials have 
shown that the antagonists of TRPV4 receptor decrease the 
voiding frequency. It has also been found that the selective 
agonists of TRPV1 receptors (capsaicin and resiniferatoxin), 
when administered as a single dose, cause the depolarisa-
tion of afferent fibres containing TRPV1 receptors. If they 
are administered multiple times, they decrease sensitivity, 
impair the functions of and completely damage the endings 
of these neurons. This produces a clinical effect in the form 
of an increase in functional bladder volume. TRPV1 receptor 
antagonists also constitute an interesting alternative in OAB 
pharmacology. They have been found to block the release of 
ATP from the urothelium induced by the bladder wall stretch-
ing, and at the same time they do not cause adverse events 
typical for TRPV1 agonists, and inhibit detrusor contractions 
induced by the administration of cyclophosphamide. Cap-
sazepine is representative for this group of compounds and 
is currently subjected to clinical tests [9].
CANNABINOID RECEPTORS
The presence of cannabinoid receptors (CB1, CB2) was 
detected in many structures of CNS. They play an impor-
tant role in voiding cycle regulation. CB1 receptors (but 
not CB2 receptors) were also found in the neurons of the 
dorsal root of the spinal nerve. A particularly high density 
of CB1 and CB2 receptors was detected in the urothelium, 
and was much higher than the level found in the detrusor 
muscle. Preclinical trials have proven that the stimulation 
of cannabinoid receptors leads to a reduction in bladder 
contractile activity. The stimulation of CB1 receptors has 
also been found to inhibit DO induced by the intravesical 
administration of NGF. This reaction could be reversed by the 
application of the selective antagonist. Synthetic analogues 
of these compounds have proven to reduce DO symptoms 
induced by nociceptive stimuli. The clinical trials have con-
firmed the high effectiveness of cannabis extract containing 
delta-9-tetrahydrocannabinol in multiple-sclerosis patients 
with urge incontinence. Thus, it seems that CB1 (and prob-
ably also CB2) receptors can constitute a potential target for 
OAB pharmacotherapy [10].
VITAMIN D3 RECEPTORS
Vitamin D3 receptors were found in the cells of urothe-
lium and the smooth muscle cells of the detrusor, and also 
in the urethra. Preclinical trials have shown that vitamin 
analogues have a relaxant effect on the bladder through the 
upregulation of L-type Ca2+ channel and ROCK inhibition. 
It was confirmed by the results of the clinical trials in which 
the authors noted that the administration of elocalcitol 
in people with OAB symptoms and features of DO, as ob-
served during the urodynamic tests, resulted in a reduction 
in the number of incontinence episodes, and a subjective 
improvement in the patient’s health condition. However, 
its effects on the DO features present in cystometry were 
not revealed. In turn, the application of elocalcitol in pa-
tients with idiopathic DO proved to increase the voiding 
and the bladder volumes at the first desire to void. This 
compound administered to people suffering from benign 
prostatic hyperplasia led to a reduction in urgency and 
daytime and night-time frequency. In turn, another vitamin 
D3 analogue (maxacalcitol) weakened the positive effects 
the ROCK inhibitors had on DO. At the same time, it was 
noted that doses of this analogue, which were ineffective 
as a monotherapy, potentialised the action of oxybutynin 
chloride and amlodipine besylate. The results of clinical trials 
have shown that the therapy with vitamin D analogues is 
welltolerated and could be used in the pharmacotherapy 
of OAB wet, especially in people who do not tolerate treat-
ment with antimuscarinics, or when such therapy proves 
ineffective [11].
OPIOID RECEPTORS
Opioids seem to affect voiding, both through their 
impacts on CNS and via receptors localised in the nerv-
ous system. The intravenous administration of tramadol 
increases the threshold micturition pressure and voiding 
volume. Used as a prolonged release agent, the drug has 
proven more effective than the placebo in its reduction of 
the number of urge-incontinence episodes. When admin-
istered epidurally, tramadol leads to an increase in bladder 
volume and susceptibility, without affecting the voiding 
phase. Also, the agonist of the opioid receptors (OP4) — no-
ciceptin is currently subjected to clinical trials. The results 
so far have shown that its intravesical instillation in patients 
with neurogenic bladder induces bladder volume increase, 
which might suggest that this group of compounds can be-
come an interesting alternative to vanilloids [12, 13].
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SUMMARY
The obtained results from both preclinical and clini-
cal trials identified new pharmacological options of OAB 
therapy which stand a good chance of being applied in 
clinical practice. It seems that they will be tailor-made and 
based on the pathophysiological mechanisms that induce 
OAB symptoms.
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